Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

Next Previous
X
Search
Trial Profile

Phase 1 study of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nalmefene (Primary) ; Nalmefene
  • Indications Opioid-related disorders
  • Focus Pharmacokinetics

    • Most Recent Events

    • 18 Apr 2018 According to Opiant Pharmaceuticals media release, the company has been awarded a grant of approximately $7.4 million from the National Institutes of Healths National Institute on Drug Abuse (NIDA) for the development of OPNT003 (intranasal nalmefene), the grant follows encouraging data from this study.
    • 20 Feb 2018 New trial record
    • 12 Feb 2018 According to Opiant Pharmaceuticals media release, company announced results. and provided an update on a meeting held February 8, 2018 with the U.S. Food and Drug Administration (FDA) regarding its planned development program.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top